Biotechnology
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment weight rebound. NEW ORLEANS, June 5, 2026 /PRNewswire/ -- Ractigen Therapeutics, a ...
2026-06-06 08:30
2267
SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver
Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281 VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech), a global leader in biotechnology solutions, today announced the launch of SYNMUE™, a clinically validated probiotic featuringLactipl...
2026-06-06 03:15
3319
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, mor...
2026-06-05 22:00
4283
Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Adminis...
2026-06-05 11:30
2110
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facil...
2026-06-05 10:45
2699
Natural Field Announces New Cartilage Health Research Findings Ahead of CPHI China 2026
XI'AN, China, June 4, 2026 /PRNewswire/ -- Natural Field recently completed a Phase I scientific evaluation study on joint health functionality. The results demonstrated that glucosamine-chondroitin co-loading liposomes exhibited significant activity in a cartilage injury repair model, providing ...
2026-06-04 23:00
3258
Global Ergothioneine Market Poised for Accelerated Growth as Scientific Validation and Synthetic Biology Reshape Industry Dynamics
New Frost & Sullivan White Paper Highlights Emerging Opportunities Across Healthy Aging, Functional Nutrition, Personal Care, and Preventive Healthcare SHANGHAI, June 4, 2026 /PRNewswire/ -- Frost & Sullivan's latest white paper, Global Ergothioneine Industry Current Landscape and Development Tre...
2026-06-04 21:35
2611
Soonr Health Officially Launches in the U.S. with Connected At-Home Fertility Tracking for Couples
With the launch of Surearly SMART on Amazon, Soonr Health now offers couples connected at-home ovulation and hormone testing, the first device in an expanding ecosystem built around dyadic health. SEOUL, South Korea, June 4, 2026 /PRNewswire/ -- Vespexx Inc., a femtech company building products ...
2026-06-04 21:00
2283
Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day
* WuXi XDC and BioDlink jointly hosted the 2026 Open Day, marking their first flagship customer-facing event following the strategic integration. * The event brought together biotech customers, industry leaders and innovators to explore how an integrated ADC/XDC CRDMO platform can accelerate ...
2026-06-04 20:30
1791
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly-owned subsidi...
2026-06-04 18:58
2278
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2026-06-04 16:35
2540
Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
GUANGZHOU, China, June 4, 2026 /PRNewswire/ -- Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development code: LP-168) for the treatment of adult patients with relapsed or refractory mantle cell lymp...
2026-06-04 16:19
2052
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
SEOUL, South Korea, June 4, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S. This milestone marks a significant step f...
2026-06-04 11:39
2159
HkeyBio New Platform Launch: AIH, PBC, and IgAN Model Matrix Empowers "One Drug, Multiple Screens" in Autoimmune New Drug R&D
BOSTON and SUZHOU, China, June 3, 2026 /PRNewswire/ -- HkeyBio announced today the launch of preclinical disease model platforms covering Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and IgA Nephropathy (IgAN). This platform integrates standardized rodent models with continuousl...
2026-06-03 22:00
2865
NIANCE Expands Beyond Products into a Global Beauty & Longevity Ecosystem
ZURICH, June 3, 2026 /PRNewswire/ -- Swiss luxury beauty brand NIANCE
2026-06-03 20:52
2339
Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-06-03 12:00
2851
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, the first-in-human study results of the novel B7...
2026-06-03 08:00
2557
Pictor® Reports Strong Commercial Momentum One Year After Launching U.S. Headquarters
The targeted proteomic platform company marks its first anniversary in Carlsbad with four commercial partnerships, seven products, BSL-2 equipped lab, and growing adoption across human and animal health markets globally CARLSBAD, Calif., June 2, 2026 /PRNewswire/ -- As laboratories increasingly ...
2026-06-02 20:48
2364
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
* Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases * Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diver...
2026-06-02 20:27
2922
SK bioscience Secures First UNICEF Procurement Contract Improving Vaccine Access
* First UNICEF procurement contract strengthens SK bioscience's presence in global public procurement markets * Dual-hemisphere supply programs enhance manufacturing efficiency and operational capabilities * Public procurement programs drive both commercial growth and improved vaccine acces...
2026-06-02 20:00
2333
Week's Top Stories
Most Reposted
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 299 media titles]
2026-06-04 23:55
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 292 media titles]
2026-06-05 15:00Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 291 media titles]
2026-06-05 19:08
FPT and NVIDIA Collaborate to Release the Nemotron Personas Vietnam Datasets
[Picked up by 276 media titles]
2026-06-05 17:34
Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Most Read
WePlay Korea's 4th Anniversary Celebration Kicks Off, Joining Hands with "Hello Panda-哈啰潘达" to Create Fu Bao Themed Space Decorations
2026-06-01 12:00
7003
NYSE Content Update: FedEx Freight to List on the NYSE + Join S&P 500
2026-06-01 21:32
6197
Hello Group Inc. Announces Unaudited Financial Results for the First Quarter of 2026
2026-06-02 15:33
5723
Mizuho becomes First Japanese Bank to Adopt SAP Multi-Bank Connectivity Solution
2026-06-02 15:00
5423
